Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Other financing activities: 2014-2024

Historic Other financing activities for Axsome Therapeutics (AXSM) over the last 9 years, with Dec 2024 value amounting to $816,000.

  • Axsome Therapeutics' Other financing activities rose 1342.22% to $3.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $4.2 million, marking a year-over-year decrease of 73.39%. This contributed to the annual value of $816,000 for FY2024, which is 94.79% down from last year.
  • Latest data reveals that Axsome Therapeutics reported Other financing activities of $816,000 as of FY2024, which was down 94.79% from $15.7 million recorded in FY2023.
  • Axsome Therapeutics' 5-year Other financing activities high stood at $15.7 million for FY2023, and its period low was $309,000 during FY2021.
  • In the last 3 years, Axsome Therapeutics' Other financing activities had a median value of $7.0 million in 2022 and averaged $7.8 million.
  • In the last 5 years, Axsome Therapeutics' Other financing activities soared by 2,157.28% in 2022 and then plummeted by 94.79% in 2024.
  • Over the past 5 years, Axsome Therapeutics' Other financing activities (Yearly) stood at $1.1 million in 2020, then crashed by 71.98% to $309,000 in 2021, then spiked by 2,157.28% to $7.0 million in 2022, then spiked by 124.63% to $15.7 million in 2023, then crashed by 94.79% to $816,000 in 2024.